Introduction
The lung is a major interface with the environment, and so pulmonary infection is a frequent consequence of both primary (congenital) immunodeficiency (PID) and acquired immunodeficiency. Haematopoietic SCT (HSCT) is the best treatment for SCID disorders, and is becoming increasingly used for other PIDs 1 as well as children with severe autoimmune disease, 2 where conventional treatment and new biologic agents have already caused severe immunocompromise. These patients are therefore at high risk of opportunistic pulmonary infection. The clinical presentation may be florid and overwhelming, but infection with poorly pathogenic organisms may be insidious. Clinical and radiographic findings are rarely diagnostic for specific infections. Pulmonary complications remain one of the most serious obstacles to the success of HSCT 1 and pulmonary infection is a significant cause of morbidity and mortality following HSCT. In the severely immunocompromised, coinfection with several different pathogens may occur. 3 Bronchoalveolar lavage (BAL) permits identification of lower respiratory tract pathogens such as Pneumocystis jiroveci (previously carinii), 4 which are not present in upper airway secretions. Identification of these pathogens is important as it may direct specific treatment, alter timing of HSCT and influence prognosis. The identification of pathogens pre-HSCT allows appropriate treatment and may avoid the need to perform diagnostic BAL immediately post-HSCT when the risks may be higher due to post-HSCT thrombocytopenia and neutropenia. 5, 6 Significant complications following BAL include deterioration in respiratory status requiring post-procedure oxygen supplementation or ventilation, post-procedure fever or apnoea. Fibre-optic bronchoscopy with BAL is widely used to investigate pulmonary abnormalities in patients undergoing treatment for malignancy or following HSCT, but there are no reports about the value of non-bronchoscopic BAL and few reports about the utility of pre-HSCT BAL. There are currently no reports about BAL pre-HSCT for patients with PID. We wished to determine the value of performing 'routine' BAL before HSCT in symptomatic and asymptomatic paediatric patients undergoing HSCT for severe immunological or autoimmune disease at our unit.
Materials and methods
A prospective study was performed on consecutive patients who were admitted to the Haematopoietic stem cell transplant unit at Newcastle General Hospital between January 2002 and April 2006 for HSCT for PID or severe autoimmune disease. Following informed consent, a routine non-bronchoscopic BAL was performed on admission at the time of central venous line insertion under general anaesthetic, a few days before commencing the pre-HSCT cytoreductive chemotherapy. A nasogastric tube was passed down the endotracheal tube until it wedged. Sterile normal saline (1 ml/kg bodyweight) was flushed down the tube and aspirated. Patients were monitored during the procedure for pulse rate, blood pressure and oxygen saturation. The procedures were performed by trained paediatric anaesthetists. Samples were aliquoted and sent to the regional microbiology laboratory for bacterial, mycobacterial, fungal detection and to the regional Health Protection Agency laboratory based at Newcastle General Hospital for viral and P. jiroveci detection. Samples were not routinely sent for cytological analysis.
Samples were cultured for respiratory pathogens using blood agar and chocolate bacitracin plates in CO 2 for 48 h; cysteine lactose electrolyte-deficient agar for 24 h in O 2 and for legionella using a specific legionella media incubated for 10 days in CO 2 . Culture for fungi was performed using Sabouraud's agar incubated at 30 and 371C for 21 days in O 2 . Culture for mycobacteria was performed using continuously automated mycobacterial liquid culture (MBBact 3D System; bioMerieux, Basingstoke, Hampshire, UK), incubated for up to 56 days. All isolates obtained were identified using conventional methods and sensitivity testing performed as appropriate.
P. jiroveci was diagnosed by indirect immunofluorescence (IF) using an unconjugated monoclonal antibody reagent (Axis-Shield Diagnostics Ltd, Dundee, UK). Respiratory syncytial virus (RSV), influenza A and B, adenovirus, human parainfluenzae virus (HPIV) 1-4 were detected by direct IF, initially using a Simufluor Respiratory Screen monoclonal antibody reagent (Light Diagnostics; Sterilab, Harrogate, North Yorkshire, UK) and any reactive specimens being tested with individual monoclonal antibody reagents (Light Diagnostics). CMV was detected by real-time PCR using a Roche Lightcycler (Roche Diagnostics Limited, Burgess Hill, West Sussex, UK). Respiratory samples were inoculated onto three cell lines: Hep-2 cells (continuous human epithelial cell line-sourced locally), PLC cells (human liver hepatoma, Alexander cell line-European collection of cell culture (ECACC), Porton Down, Salisbury, UK) and human diploid cells, MRC5 (human fetal lung, semi-continuous cell line-ECACC). Cultures were examined every other day for cytopathic effect and discarded, if negative, after 14-16 days.
Human herpes virus 6 (HHV6) was sought by real-time PCR using a Roche Lightcycler, in patients with evidence of HHV6 in other sites (blood and biopsy material), but was not performed routinely.
Patients were categorized before the procedure as symptomatic or asymptomatic with respect to pulmonary disease or infection. Symptomatic patients with preexisting lung disease were defined as those with one or more of the following:
abnormalities on a plain chest radiograph or computerized tomography an oxygen requirement other respiratory support
Complications arising from the procedure, pathogens isolated and treatment instituted were recorded. Fever was defined as 437.51C axillary temperature, measured by electronic thermometer. Subsequent care was influenced by the pathogen isolated, if any. Appropriate antimicrobial treatment was instituted, and the transplant was postponed if clinically indicated. Repeat BAL was not routinely performed. Nasopharyngeal secretions were collected at admission, by suctioning the nasopharynx. Nose and throat swabs were taken at the same time. These specimens were repeated weekly through the transplant period.
Statistical analysis was performed using the software package GB-Stat PPCworks 6.5.4 (Dynamic Microsystems Inc., Silver Spring, MD, USA). The w 2 -test was utilized to compare groups. A P-value o0.05 was considered to be significant.
Results
Seventy-five patients with SCID (27), other PID (43) or severe autoimmune disease (8) were admitted for HSCT during the study period. Patient demographics for those 69 patients who underwent a routine BAL are listed (Table 1) . Patients were receiving prophylactic antimicrobial therapy before the BAL, as part of routine care, which consisted of co-trimoxazole, aciclovir, itraconazole and immunoglobulin replacement, the specific prophylactic regimen depending on the underlying immunodeficiency. Five did not have BAL performed. Of these, one died of overwhelming disseminated adenovirus infection before the procedure was performed, and four did not have the procedure performed, for nonspecified reasons. Of these four patients, three were asymptomatic. In another patient, BAL was performed, but the sample leaked from the transport container before any investigations were undertaken. No patients underwent routine directed fibre-optic bronchoscopy, as none presented with isolated lesions on chest radiography.
Results were available from 69 patients (92%), who underwent non-bronchoscopic BAL at the time of insertion of a central venous catheter, before starting preparative chemotherapy. Twenty-six patients (38%) had pathogens identified. Ten (14.5%) developed complications following the procedure. Treatment was commenced empirically at first, and then modified when antimicrobial sensitivity information was available. The decision to postpone or continue with transplantation was made on an individual basis, and depended on the diagnosis, the organism isolated and the clinical condition of the patient.
Symptomatic patients
Thirty-nine patients (57%) who were symptomatic underwent non-bronchoscopic BAL. Twenty (51%) had pathogens identified. This included 11 patients with P. jiroveci, of whom 3 had viral co-pathogens (rhinovirus (patient 25), RSV (patient 50), CMV and HPIV-3 (patient 65; Table 2 ). Nine other symptomatic patients (23%) without pneumocystis had pathogens identified from BAL fluid ( Table 2) . Of these, six had virus and six had bacteria identified.
Four patients with pneumocystis, and one with viral isolates (patient 72) developed complications following the procedure (assisted ventilation for 5 days (1), increased oxygen requirement (1), oxygen desaturation (1), mild subcostal recession (1), fever and increased respiratory effort (1)). Three symptomatic patients in whom no pathogen was isolated developed complications (assisted ventilation for inflammatory pneumonitis (1), oxygen desaturation-procedure abandoned (1), increased oxygen requirement (1)); all recovered uneventfully.
Asymptomatic patients
Thirty patients (43%) who were asymptomatic at presentation underwent routine non-bronchoscopic BAL. Six (20%) had potentially pathogenic organisms identified and in five patients, treatment was instituted on the basis of the microbiological isolate (Table 3) . Unexpectedly, P. jiroveci was identified from patient 75, who was treated with high-dose co-trimoxazole before conditioning chemotherapy. None of these six patients developed complications following the procedure. Of the remaining 24 patients, from whom no isolate was obtained, 2 (8%) had mild complications, 1 developed fever of 37.51C and 1 preterm infant developed self-limiting apnoeas.
There was no statistically significant difference in either the number of positive isolates from the SCID or other PID population, or of patients who were symptomatic or asymptomatic-nevertheless, 6 (20%) of 30 patients who were asymptomatic had an organism identified, which in the five cases led to a change of management. Fifty-one per cent of symptomatic patients had pathogens identified, of which half were P. jiroveci. Of these, three had other co-pathogens.
All patients recovered completely after the procedure. Ten of sixty-nine patients (14.5%) undergoing BAL developed complications, but only 2/30 (7%) asymptomatic patients who received a routine BAL developed complications, which were self-limiting.
Of the six asymptomatic patients, two had information from the BAL that added to information obtained from nasopharyngeal secretions (Table 1) . Of the 20 symptomatic patients, 14 had information from the BAL that added to information obtained from nasopharyngeal secretions (Table 2) .
Four patients underwent a repeat procedure before HSCT for a change in respiratory status not associated with the initial procedure (patients 6, 22, 40 and 49)-no organisms were identified on the repeat procedure.
Discussion
The data presented in this report suggest that for patients undergoing HSCT for PID, BAL is of substantial value. In symptomatic patients, it directed treatment or altered management in 51%. It is of note that this was also true for patients without respiratory symptoms. First, a relatively high proportion of asymptomatic patients had a diagnostic procedure that altered management and, hence, potentially altered the outcome of HSCT, particularly for patient 75, who would have received myeloablative chemotherapy with untreated P. jiroveci. Second, the incidence of complications in the asymptomatic group was low, with only 2/30 patients developing mild complications. Even in our symptomatic group, the incidence of complications (21%) was lower compared with other Table 1 Diagnoses and age at time of procedure in the patients who underwent routine bronchoalveolar lavage published series that documented 48 and 30.6% complications in symptomatic patients. 6, 7 In part, this may be due to the use of lower fluid volume to perform the BAL.
The advantages of fibre-optic BAL are an ability to investigate directly the lung area that is affected specifically, and this should be the investigation of choice in patients with focal lung lesions. However, despite our use of nonbronchoscopic BAL, our diagnostic yield of 39% compares favourably with other series that have reported yields of 30, 37 and 73%, respectively. [7] [8] [9] The yield is higher if one looks at only symptomatic patients (54%). Polymicrobial infections have previously been reported in SCID patients undergoing HSCT. 3 Eight of the twenty-six patients who had a positive isolate had more than one organism identified.
Four symptomatic patients who had organisms isolated pre-HSCT subsequently died post-HSCT. Two died of complications relating to the organism isolated at BAL. Four patients who were symptomatic but from whom no organisms were isolated also died, all of complications relating to HSCT or underlying PID, but none due to infective lung complications. Four patients who were asymptomatic also died; none had organisms isolated from BAL, and all died of complications arising from GVHD.
Fever complicating BAL is well recognized and appears to be associated with BAL rather than bronchoscopy. It occurs more frequently with larger volume lavage and coexistent pulmonary infection. A rate of 50% has been reported with 200 ml lavage in normal adult volunteers, 5 but the volume used in our series was only 1 ml/kg, which may explain the low incidence of fever found.
BAL is an important tool in the evaluation of PID patients pretransplantation, and, as in our series, clinically relevant information additional to that obtained from nasopharyngeal secretions may be acquired. For those with respiratory symptoms, BAL is mandatory, and has a high diagnostic yield, particularly, when new microbiological detection methods are employed. 9, 10 Identification of Table 2 Microbiological isolates from bronchoalveolar lavage specimens in symptomatic patients pathogens may allow specific treatment and alerts the clinician to the possibility of complications post-HSCT. The possibility of complications arising during the BAL procedure is usually outweighed by the potential benefit from the diagnostic information gained as a result of the procedure. Previous series have reported on fibre-optic bronchoscopic-directed BAL but this is the first report of the outcome of routine non-bronchoscopic BAL in patients with PID undergoing HSCT. The decision about whether asymptomatic patients should be routinely subjected to invasive diagnostic procedures, with the potential for adverse effects arising, is more controversial. Non-bronchoscopic BAL performed post-HSCT may be necessary in specific cases, but, at least in the early period post-HSCT when patients are most vulnerable to infection and haemorrhage secondary to thrombocytopaenia, the rate of complications is higher. 5, 6 Non-bronchoscopic BAL performed routinely in PID patients about to undergo HSCT is safe, even in asymptomatic subjects. There is a good diagnostic yield, especially in symptomatic patients, but unexpected isolates may be identified in asymptomatic patients. For a number of our asymptomatic patients the results of BAL resulted in a change of management. P. jiroveci was found in asymptomatic as well as symptomatic patients. We recommend non-bronchoscopic BAL as a routine procedure in PID patients, or those with severe autoimmune disease about to undergo HSCT, because it is an important part of the diagnostic evaluation, with a high yield, that often leads to management changes and a low rate of significant complications. BAL improves diagnostic yield and is important for directing specific treatment. Our complication rate was less than those reported for fibre-optic BAL suggesting that this is a low-risk.
